113 In the index

Larazotide LARA

An experimental medication studied in human trials as an add-on treatment for celiac disease, aimed at reducing symptoms from accidental gluten exposure. Results have been mixed, with some trials not meeting their goals, and it remains unapproved.

Also known as AT-1001, Larazotida, Larazotide [USAN:INN], AT 2347, ZN3R5560ZV, larazotidum, Larazotide [INN], RefChem:798506

Effects Heal

Routes Oral

Legal status Unapproved / investigational

WADA Not listed

Molecular Structure of C₃₂H₅₅N₉O₁₀

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C32H55N9O10
Molar mass: 725.8
CAS: 258818-34-7
PubChem CID: 9810532
IUPAC name: 2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
InChIKey: ORFLZNAGUTZRLQ-ZMBVWFSWSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; investigational

Reported range Phase III trial doses: 0.5-2 mg, taken before meals

Route Oral

Frequency Up to 3 times daily, before meals (trial protocol)

Duration Trial durations of several months

Investigational tight-junction regulator studied as an adjunct therapy for celiac disease; not an approved product as of this writing.

Where this comes from Published Phase III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.